Blogroll
- Ben’s Stem Cell News
- Biosingularity
- Biotech Blog
- Cell WISE
- CellTherapyBlog
- CellTherapyNews
- Fierce Biotech
- Fredrick County, MD Biotech Community
- Hematopoiesis
- IN VIVO blog
- Life Sciences Chronicle
- List of Biotech Conferences
- My Biotech Life
- Partial Immortalization
- Stem Cell Patents
- The Niche
- The Stem Cell
- US PTO
- Venture Beat – Lifesciences
- Wired Blogs – Science
- WordPress.com
Cool Regenmed Jobs
- Biomaterials and Diabetes Scientists at Living Cell Technologies (New Zealand)
- Cell and Tissue Culture Technicians at Pharmacell (ex-US)
- Cell Culture, Bioprocess, Analytical, and Tissue Engineering positions open at Tengion
- Cell Process Development and Production Positions at Cognate Bioservices
- Cell Therapy Business Development Leader at Invitrogen
- Jobs at Geron: chemists, process and product development, cell biology, immunology, assay development, and quality positions
- Manufacturing Manager at Cognate Bioservices
- Process Dev, R&D, Quality and other jobs at Tigenix (Belgium and US)
- RegenMed Scientists and Research Associates at Athersys
- Research and Quality positions at Biomimetic Therapeutics
General Science
Local Biotech Gateways
Other Biotech Blogs
Patents
Archives
Catagory Cloud
adult stem cell Advanced Cell Technology Apptec Athersys BD Big Pharma Biomaterials Bioprocessing business models cardiac regeneration cell delivery Clinical Trials combination products Company Profiles Embyonic Stem Cells FDA Geron Innovation Intellectual Property Invitrogen JNJ Job search Joint Ventures Manufacturing Novocell Osiris Regenerative Medicine regulatory stem cells vascular regeneration
Category Archives: MSCs
Osiris Scores $225M DoD Contract for Acute Radiation Syndrome Treatment with Prochymal Adult Stem Cell Product
Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued … Continue reading
Athersys’ adult allogeneic stem cell IND gets OK from FDA
On November 15, 2007, Athersys announced in a press release that they had received a letter from the FDA giving the green light to start a Phase I safety study of MultiStem, their adult, allogeneic stem cell product. Athersys will … Continue reading
Posted in adult stem cell, Athersys, Clinical Trials, FDA, MSCs, Osiris, Regenerative Medicine, stem cells
Tagged adult stem cells, Athersys, business model, stem cells clinical trials
1 Comment
The Regeneration Station 